TY - JOUR
T1 - Autologous Stem Cell Transplantation and Multiple Myeloma Cancer Stem Cells
AU - Matsui, William
AU - Borrello, Ivan
AU - Mitsiades, Constantine
PY - 2012/1
Y1 - 2012/1
N2 - It is well established that high-dose therapy (HDT) combined with autologous stem cell transplantation (ASCT) produces superior response rates and progression-free survival compared with conventional chemotherapy in patients with multiple myeloma (MM). Accordingly, MM currently represents the most common indication for ASCT. Despite these clinical improvements, the impact of ASCT on overall survival is unclear because the vast majority of patients eventually experience disease relapse and progression. The continual risk of relapse suggests that malignant cells resistant to HDT possess the clonogenic growth potential to mediate tumor regrowth, and in several diseases cancer stem cells (CSCs) have been identified that are both highly tumorigenic and resistant to standard anticancer approaches. Putative CSCs have been identified in MM, and their characterization may lead to the development of novel maintenance strategies that inhibit the production of new tumor cells, prevent disease relapse, and improve overall survival.
AB - It is well established that high-dose therapy (HDT) combined with autologous stem cell transplantation (ASCT) produces superior response rates and progression-free survival compared with conventional chemotherapy in patients with multiple myeloma (MM). Accordingly, MM currently represents the most common indication for ASCT. Despite these clinical improvements, the impact of ASCT on overall survival is unclear because the vast majority of patients eventually experience disease relapse and progression. The continual risk of relapse suggests that malignant cells resistant to HDT possess the clonogenic growth potential to mediate tumor regrowth, and in several diseases cancer stem cells (CSCs) have been identified that are both highly tumorigenic and resistant to standard anticancer approaches. Putative CSCs have been identified in MM, and their characterization may lead to the development of novel maintenance strategies that inhibit the production of new tumor cells, prevent disease relapse, and improve overall survival.
UR - http://www.scopus.com/inward/record.url?scp=84855416310&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84855416310&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2011.10.036
DO - 10.1016/j.bbmt.2011.10.036
M3 - Article
C2 - 22226109
AN - SCOPUS:84855416310
SN - 1083-8791
VL - 18
SP - S27-S32
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 1 SUPPL.
ER -